APM
IMNM icon

Avidity Partners Management’s Immunome IMNM Stock Holding History

Avidity Partners Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-873,891
Closed -$12.8M – 74
2024
Q3 		$12.8M Hold
873,891
– – 0.65% 56
2024
Q2 		$10.6M Hold
873,891
– – 0.45% 61
2024
Q1 		$21.6M Sell
873,891
-459,588
-34% -$9.33M 0.7% 47
2023
Q4 		$14.3M Buy
+1,333,479
New +$11.1M 0.52% 53

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avidity Partners Management's IMNM Position: Q4 2024 in Review

Avidity Partners Management sold out of Immunome (IMNM) in Q4 2024, closing a stake of 873,891 shares — an estimated $12.8M sold.

Avidity Partners Management first reported a position in IMNM in Q4 2023 and held it in 4 quarters. The position peaked at $21.6M in Q1 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

  • Avidity Partners Management reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
  • Avidity Partners Management sold 873,891 Immunome shares in Q4 2024, an estimated $12.8M.
  • Avidity Partners Management first reported a position in Immunome in Q4 2023 and held it in 4 quarters.
  • Avidity Partners Management's Immunome position peaked at $21.6M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.